
|Articles|July 15, 2004
Verteporfin-maker QLT to merge with Atrix
Vancouver, British Columbia-An $855 million deal will unite verteporfin (Visudyne) developer QLT Inc. and Atrix Laboratories Inc. to build QLT's business and accelerate strategic initiatives.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA grants IDE approval to EyeYon Medical for its US clinical study of EndoArt
2
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
3
First patient treated in ViaLase’s IDE trial
4
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
5















































.png)


